Notícias e Atividades da Ironwood Pharmaceuticals

Ironwood Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Ironwood Pharmaceuticals é uma empresa listada sob o símbolo IRWD (US).

Fusão, aquisição e financiamento envolvendo Ironwood Pharmaceuticals.

• Ironwood Pharmaceuticals has announced the acquisition of VectivBio  (publicado em 25 de maio de 2023).

Veja o organograma con seus 20 executivos principais

Biografias mais buscadas da Ironwood Pharmaceuticals

• Thomas McCourt, Chief Executive Officer and Director
• Catherine Moukheibir, Director
• Julie McHugh, Chairman of the Board

Recentes movimentos de executivos em Ironwood Pharmaceuticals

• Tammi Gaskins antes Vice President of Brand Management, foi promovido a Senior Vice President and Chief Commercial Officer  (Notícia publicada em 30 de janeiro de 2025).
• Sravan Emany, Senior Vice President, Chief Financial Officer and Chief Operations Officer, deixou a Companhia  (Notícia publicada em 30 de dezembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Ironwood Pharmaceuticals

• Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
• Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
• Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
• Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
• Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
• Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
• Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
• Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
• Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
• Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
• View more press releases Close

Redes sociais sobre Ironwood Pharmaceuticals

• Ironwood Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Ironwood Pharmaceuticals na LinkedIn, Twitter e YouTube